Temafloxacin is an antibiotic agent belonging to the fluoroquinolone drug class. It was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the... It was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three deaths.
- Mechanism
- Curator reviewed
The bactericidal action of temafloxacin results from interference with the activity of the bacterial enzymes DNA gyrase and topoisomerase IV, which are needed for the transcription and replication of bacterial DNA. DNA gyrase appears to be the primary quinolone target for gram-negative bacteria. Topoisomerase IV appears to be the preferential target in gram-positive organisms. Interference with these two topoisomerases results in strand breakage of the bacterial chromosome, supercoiling, and resealing. As a result DNA replication and transcription is inhibited.
- Primary indication
- For the treatment of lower respiratory tract infections, genital and urinary infections like prostatitis, and skin infections.Curator reviewed
- Formula / weight
- C21H18F3N3O3 · 417.3811 g/mol (avg)
Resolves to
QKDHBVNJCZBTMR-UHFFFAOYSA-NSMILESCC1CN(CCN1)C1=C(F)C=C2C(=O)C(=CN(C2=C1)C1=C(F)C=C(F)C=C1)C(O)=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Temafloxacin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account